托法替布治疗中国活动性银屑病关节炎患者的疗效与安全性:一项3期、随机、双盲、安慰剂对照研究
这项为期6个月的双盲3期研究纳入对至少一种传统合成改善病情抗风湿药应答不足的中国活动性银屑病关节炎患者,按2:1随机接受托法替布5 mg每日两次(N=136)或安慰剂(N=68),主要终点为第3个月ACR50应答率,托法替布组38.2% vs 安慰剂组5.9%(p<0.0001),达到主要终点;托法替布耐受性良好,安全性特征与已知一致。
要点
- 第3个月ACR50应答率托法替布5 mg每日两次组为38.2%,安慰剂组为5.9%(p<0.0001)。
- 第3个月ACR20/ACR70/PASI75应答率及附着点炎、指趾炎消退率托法替布组均高于安慰剂组,HAQ-DI改善更大。
- 托法替布组报告1例严重感染、1例非严重带状疱疹和1例肺癌,未报告非黑色素瘤皮肤癌、主要心血管不良事件或血栓栓塞事件。
核心结论
- 在中国银屑病关节炎患者中,托法替布疗效优于安慰剂(主要和次要终点)。
- 托法替布耐受性良好,安全性结局与银屑病关节炎及其他适应症的已知安全性特征一致。
研究设计与样本
- 为期6个月的双盲3期研究,纳入中国活动性(多关节型)银屑病关节炎且对至少一种传统合成改善病情抗风湿药应答不足的患者。
- 患者按2:1随机接受托法替布5 mg每日两次(N=136)或安慰剂(N=68),第3个月后(盲态下)转为托法替布5 mg每日两次。
- 主要终点为第3个月美国风湿病学会(ACR)50应答。
主要发现
- 主要终点达到:托法替布5 mg每日两次组第3个月ACR50应答率38.2%,安慰剂组5.9%(p<0.0001)。
- 第3个月ACR20、ACR70、PASI75应答率以及附着点炎和指趾炎消退率托法替布5 mg每日两次组高于安慰剂组,HAQ-DI降低幅度托法替布5 mg每日两次组大于安慰剂组。
- 第0–3个月不良事件/严重不良事件发生率:托法替布5 mg每日两次组68.4%/0%,安慰剂组75.0%/4.4%。
- 安慰剂→托法替布5 mg每日两次组报告1例死亡(事故所致)。
- 第0–6个月托法替布5 mg每日两次组各报告1例严重感染、非严重带状疱疹和肺癌;安慰剂→托法替布5 mg每日两次组报告4例严重感染和1例非严重带状疱疹;未报告非黑色素瘤皮肤癌、主要心血管不良事件或血栓栓塞事件。
关键数值与推荐
- 主要终点:第3个月ACR50应答率托法替布5 mg每日两次组38.2% vs 安慰剂组5.9%(p<0.0001)。
- 第0–3个月不良事件发生率:托法替布5 mg每日两次组68.4% vs 安慰剂组75.0%;严重不良事件发生率:托法替布5 mg每日两次组0% vs 安慰剂组4.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug. METHODS: Patients were randomised (2:1) to tofacitinib 5 mg twice daily (N=136) or placebo (N=68); switched to tofacitinib 5 mg twice daily after month (M)3 (blinded). PRIMARY ENDPOINT: American College of Rheumatology (ACR50) response at M3. Secondary endpoints (through M6) included: ACR20/50/70 response; change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI); ≥75% improvement in Psoriasis Area and Severity Index (PASI75) response, and enthesitis and dactylitis resolution. Safety was assessed throughout. RESULTS: The primary endpoint was met (tofacitinib 5 mg twice daily, 38.2%; placebo, 5.9%; p<0.0001). M3 ACR20/ACR70/PASI75 responses, and enthesitis and dactylitis resolution rates, were higher and HAQ-DI reduction was greater for tofacitinib 5 mg twice daily versus placebo. Incidence of adverse events (AEs)/serious AEs (M0-3): 68.4%/0%, tofacitinib 5 mg twice daily; 75.0%/4.4%, placebo. One death was reported with placebo→tofacitinib 5 mg twice daily (due to accident). One serious infection, non-serious herpes zoster, and lung cancer case each were reported with tofacitinib 5 mg twice daily; four serious infections and one non-serious herpes zoster case were reported with placebo→tofacitinib 5 mg twice daily (M0-6). No non-melanoma skin cancer, major adverse cardiovascular or thromboembolism events were reported. CONCLUSION: In Chinese patients with PsA, tofacitinib efficacy was greater than placebo (primary and secondary endpoints). Tofacitinib was well tolerated; safety outcomes were consistent with the established safety profile in PsA and other indications. TRIAL REGISTRATION NUMBER: NCT03486457.
引用
- Leng X, Lin W, Liu S, et al. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2023. PMID: 36720560. doi:10.1136/rmdopen-2022-002559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。